Preparation method and application of biocompatible metal selenide quantum dots
By using biocompatible metal selenide quantum dots as electrocatalysts and co-reactants, the problems of low efficiency of electrocatalysts and high toxicity of co-reactants in trippyridine electrochemiluminescence system are solved, and high efficiency, low toxicity and low Contaminated electrochemiluminescence reaction simplifies the preparation process and increases the electrooxidation rate.
Patent Information
- Application Number
- CN202411192670.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-06
AI Technical Summary
In the prior art, the trippyridine electrochemiluminescence system lacks efficient and biocompatible electrocatalysts, and common co-reactants such as trippropylamine have toxicity, volatility and corrosive problems, which are difficult to replace.
Using biocompatible metal selenide quantum dots, such as tungsten selenide quantum dots, as electrocatalysts and co-reactants, adjust the pH value by mixing with amino and thiol-containing molecules, and using ultra-high-speed centrifugation to ensure their biological function. Compatibility and efficiency.
It realizes an efficient, low toxicity and low pollution electrochemiluminescence reaction, improves the electrooxidation rate, enhances the electrochemiluminescence intensity, and simplifies the preparation process, with the advantages of rapid, gentle and large-scale preparation.
Smart Images

Figure CN119081698A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of novel nanomaterial preparation, and specifically relates to a preparation method of biocompatible metal selenide quantum dots and application thereof. Background Art
[0002] Electrochemiluminescence (ECL) is a chemiluminescence triggered by electrochemical methods. Electrochemiluminescence does not require the use of an external light source. Electrochemiluminescence detection has become an important detection method with the advantages of low background, high sensitivity, and simple equipment. Tris-bipyridine ruthenium (Ru(bpy)3Cl2) is an important electrochemiluminescent reagent with high luminescence efficiency. As an electrochemiluminescent reagent, tert-bipyridine ruthenium also requires a co-reactant to work together to produce an electrochemiluminescent signal.
[0003] At present, alkylamines are commonly used as co-reactants when terpyridine ruthenium is used as an electrochemiluminescent reagent. Among them, tripropylamine (TPA) as a co-reactant for terpyridine ruthenium is a successful example in commercial electrochemiluminescent immunoassay. However, tripropylamine has poor water solubility, toxicity, corrosiveness and volatility. Although people have extensively studied alternative co-reactants, some other co-reactants have also been explored, such as: H2C2O4, K2S2O8, although they have good water solubility and low toxicity, their efficiency is often greatly reduced compared with tripropylamine. From the perspective of reaction kinetics, accelerating the electro-oxidation rate of terpyridine ruthenium is an important way to make up for the efficiency limitation of the core reactant, but there are few reports on it. However, although a variety of electrocatalysts have been explored in application fields such as oxygen reduction reaction (ORR), oxygen evolution reaction (OER) and fuel cells, it is still a challenge to develop efficient and biocompatible electrocatalysts for terpyridine ruthenium electrochemiluminescence systems. Most noble metal nanoparticles and transition metal dihalide (TMDC) quantum dots, such as gold nanoclusters and CdSe quantum dots, have good catalytic ability, abundant active edge sites and favorable electronic structure, and have great potential to become ideal electrocatalysts for terpyridine ruthenium electrochemiluminescence systems. However, they are usually stabilized by a protective layer, which usually quenches the free radicals in the system and reduces the electrochemiluminescence efficiency. Based on this, it is feasible to design an electrocatalyst for the terpyridine ruthenium electrochemiluminescence system that does not have a quenching effect on free radicals, has co-reactant characteristics and maintains high biocompatibility. Summary of the invention
[0004] Purpose of the invention: In view of the problems existing in the prior art, the present invention proposes a method for preparing biocompatible metal selenide quantum dots, such as a method for preparing tungsten selenide quantum dots, and is a method for preparing biocompatible metal selenide quantum dots, which solves the problem that there are few methods for synthesizing tungsten oxide, molybdenum oxide quantum dots or biocompatible oxide quantum dots and biocompatible molybdenum oxide quantum dots in the prior art, and has the advantages of simple preparation process, mild preparation conditions (at room temperature and atmospheric conditions), fast (5 minutes) and large-scale preparation.
[0005] The present invention also provides the use of the biocompatible metal selenide quantum dots as a coreactant in an electrochemiluminescent reaction. The present invention uses biocompatible metal selenide quantum dots as a coreactant in an electrochemiluminescent reaction, which has low cytotoxicity, low pollution and high electrochemiluminescent efficiency.
[0006] Technical solution: In order to achieve the above-mentioned purpose, the method for preparing biocompatible metal selenide quantum dots of the present invention comprises the following steps:
[0007] (1) dissolving a VIB Group metal salt in water to obtain a VIB Group metal salt aqueous solution;
[0008] (2) dissolving selenium powder in sodium borohydride to obtain a selenium precursor solution;
[0009] (3) mixing and stirring a VIB group metal salt solution with molecules containing amino groups and thiol groups, adding a selenium precursor solution, and adjusting the pH value to react;
[0010] (4) ultra-high speed centrifugation is performed on the above system, and the supernatant is obtained, which is the biocompatible metal selenide quantum dots.
[0011] Wherein, the VIB Group metal salt in step (1) is sodium tungstate, sodium molybdate or sodium chromate.
[0012] Wherein, the mass ratio of the VIB group metal salt to the selenium powder in step (3) is 1:50-100.
[0013] Wherein, the molecule containing amino group and thiol group in step (3) is bovine serum albumin (BSA), cysteine or mercaptoethylamine.
[0014] Wherein, in step (3), HCl is used to adjust the pH of the solution to 6-7, and the reaction time is 4-5 minutes.
[0015] In step (4), the ultra-high speed centrifugation should be 100000G for 10 min.
[0016] Preferably, the preparation process of the biocompatible selenide quantum dots (taking WSe2@BSA quantum dots as an example) comprises the following steps:
[0017] (1) dissolving sodium tungstate in water to obtain an aqueous solution of sodium tungstate;
[0018] (2) dissolving selenium powder in sodium borohydride to obtain a selenium precursor solution;
[0019] (3) mixing the sodium tungstate solution with bovine serum albumin;
[0020] (4) Stirring the above solution thoroughly, and adding selenium precursor solution while stirring;
[0021] (5) adding hydrochloric acid dropwise into the above system to adjust the pH value;
[0022] (6) The above system is subjected to ultra-high speed centrifugation, and the supernatant is obtained, which is a dispersed system of quantum dots such as tungsten selenide.
[0023] Wherein, the sodium tungstate and water described in step (1) should be taken in 0.25 mg and 1 mL respectively, and then mixed. Preferably, ultrasonic dissolution should be selected.
[0024] Wherein, the selenium powder and sodium borohydride described in step (2) should be taken in 40 mg and 1 mL respectively, then mixed and dissolved at room temperature.
[0025] The sodium tungstate solution in step (3) should be 0.32 mL of the sodium tungstate solution obtained in step (1), the concentration of bovine serum albumin should be 0.5 mg / mL, and the volume should be 15 mL. The two should be fully mixed.
[0026] The selenium precursor solution in step (4) is 128 μL of the selenium precursor solution obtained in step (2), which is dripped into the solution obtained in step (3) while stirring. Preferably, the rotation speed of the magnet is 1000 rpm during stirring.
[0027] Wherein, the concentration of hydrochloric acid in step (5) should be 1 mol / L, and the pH should be adjusted to 6-7.
[0028] In step (6), the ultracentrifugation should be 100,000G for 10 min, and the supernatant should be taken out with a pipette and placed in a new clean test tube.
[0029] Biocompatible metal selenide quantum dots prepared by the preparation method of the present invention.
[0030] The invention discloses an application of the biocompatible metal selenide quantum dots as co-reactants in electrochemiluminescence reactions.
[0031] Wherein, when the biocompatible metal selenide quantum dots are used as a co-reactant in the electrochemiluminescence reaction, terpyridine ruthenium (Ru(bpy)3Cl2) or its derivatives are used as electrochemiluminescence reagents.
[0032] Preferably, when the biocompatible metal selenide quantum dots are used as a co-reactant in the electrochemiluminescent reaction, terpyridine ruthenium is used as an electrochemiluminescent reagent.
[0033] Wherein, biocompatible metal selenide quantum dots are added to the solution of terpyridine ruthenium or its derivatives, and the electrochemiluminescence signal is detected by an electrochemiluminescence workstation, specifically, the electrochemiluminescence signal is detected by a three-electrode system of the electrochemical workstation.
[0034] Preferably, the terpyridine ruthenium solution and the biocompatible metal selenide quantum dot solution include a PBS buffer solution with a pH of 7.4; that is, the terpyridine ruthenium solution and the biocompatible metal selenide quantum dot solution are formed with a PBS buffer solution with a pH of 7.4 as the mother solution.
[0035] Preferably, the concentration of the terpyridine ruthenium (Ru(bpy)3Cl2) solution is 50 μM, the concentration of the biocompatible metal selenide quantum dot solution is 0.1 mg / mL, and the pH of the PBS buffer solution is 7.4.
[0036] The electrochemiluminescent system of the present invention comprises biocompatible metal selenide quantum dots as co-reactants of the electrochemiluminescent reaction and terpyridine ruthenium as an electrochemiluminescent reagent, wherein the biocompatible metal selenide quantum dots are prepared biocompatible metal selenide quantum dots.
[0037] The electrochemiluminescent sensor of the present invention comprises biocompatible metal selenide quantum dots as co-reactants of the electrochemiluminescent reaction, terpyridine ruthenium as an electrochemiluminescent reagent, and a three-electrode system, wherein the biocompatible metal selenide quantum dots are prepared biocompatible metal selenide quantum dots.
[0038] Furthermore, the electrochemiluminescent system includes biocompatible metal selenide quantum dots as co-reactants for the electrochemiluminescent reaction and terpyridine ruthenium as an electrochemiluminescent reagent; the electrochemiluminescent sensor includes biocompatible metal selenide quantum dots as co-reactants for the electrochemiluminescent reaction, terpyridine ruthenium as an electrochemiluminescent reagent, and a three-electrode system.
[0039] Preferably, the electrochemiluminescent sensor comprises biocompatible metal selenide quantum dots as co-reactants of the electrochemiluminescent reaction, terpyridine ruthenium as an electrochemiluminescent reagent, a glassy carbon electrode as a working electrode, a silver-silver chloride electrode as a reference electrode, and a platinum wire electrode as a counter electrode.
[0040] Preferably, the biocompatible metal selenide quantum dots are tungsten selenide quantum dots (WSe2@BSA).
[0041] Several co-reactants have been explored for ECL systems based on ruthenium terpyridine (Ru(bpy)3Cl2), including H2C2O4, K2S2O8, and tripropylamine (TPrA), with the latter being the most popular commercial choice due to its high efficiency. To address the high biotoxicity, high volatility, and high corrosiveness of the co-reactants that have been explored so far, other co-reactants such as polymer quantum dots, carbon nano-quantum dots, and boron nitride quantum dots have been developed, but few of them can match TPrA in Ru(bpy)3Cl2 ECL efficiency.
[0042] From the perspective of reaction kinetics, the overall ECL intensity is high. Although a lot of research has been conducted to improve the performance of co-reactants and the redox reaction between emitters and co-reactants, improving the electro-oxidation rate of emitters has received less attention. However, despite the exploration of a variety of electrocatalysts for applications such as oxygen reduction reaction (ORR), oxygen evolution reaction (OER), and fuel cells, it is still a challenge to develop efficient and biocompatible electrocatalysts for the ECL of Ru(bpy)3Cl2. Most noble metal nanoparticles and transition metal dichalcogenide (TMDC) dots, such as CdSe quantum dots, have great potential to become ideal electrocatalysts for Ru(bpy)3Cl2 ECL due to their good catalytic ability, abundant active edge sites, and favorable electronic structure. Unfortunately, they are usually stabilized by protective layers, which usually quench the free radicals generated by the system. Therefore, it is relatively feasible to design an electrocatalyst for the ECL of Ru(bpy)3Cl2 that does not have a quenching effect on free radicals, while having co-reactant properties and maintaining high biocompatibility.
[0043] The present invention selects metal selenide quantum dots as electrocatalysts, and molecules containing amino and sulfhydryl groups (such as bovine serum albumin, cysteine, and mercaptoethylamine) as co-reactants and protective agents, that is, the protective agent is not only used as a protective agent for the catalyst, but also as a co-reactant for the terpyridine ruthenium luminescence system, to obtain a co-reactant of Ru(bpy)3Cl2 ECL with high efficiency, good biocompatibility, and mild preparation conditions. The present invention designs a noble metal nanocluster or transition metal dihalide (TMDC) quantum dot with good catalytic ability for the terpyridine ruthenium electrochemical luminescence system, and selects a suitable protective agent for it, which will not quench the free radicals generated by the system. On this basis, biocompatibility (low toxicity) and the difficulty and conditions of preparation are taken into account. Compared with tripropylamine, the efficiency of the co-reactant of the present invention is comparable to that of tripropylamine, but the co-reactant has good biocompatibility (low cytotoxicity), good water solubility, and mild and fast preparation conditions; compared with other co-reactants, the co-reactant has higher efficiency and is relatively easy to prepare.
[0044] The present invention prepares a new catalyst for redox reaction (such as quantum dot WSe2@BSA) and applies it to Ru(bpy)3Cl2 ECL to improve the electro-oxidation rate of Ru(bpy)3Cl2 to compensate for the efficiency limitation of the co-reactant. The present invention selects a specific protective agent for the catalyst to ensure that the protective agent does not quench the free radicals generated by the system and reduce the electrochemical luminescence efficiency. The protective agent needs to be used as a co-reactant of Ru(bpy)3Cl2 ECL, that is, a molecule containing amino and thiol groups, such as BSA, is used as a protective agent for quantum dots and a co-reactant for the terpyridine ruthenium luminescence system.
[0045] The present invention starts from the perspective of reaction kinetics and finds that accelerating the electro-oxidation rate of Ru(bpy)3Cl2 is an important way to make up for the efficiency limitation of the co-reactant. Therefore, it is necessary to screen a reagent with high electrocatalytic efficiency to catalyze the rapid oxidation of Ru(bpy)3Cl2 to make up for the efficiency limitation of the co-reactant. The present invention has previously explored a variety of electrocatalysts for applications such as oxygen reduction reaction (ORR), oxygen evolution reaction (OER) and fuel cells, including transition metal dihalide quantum dots, which have good catalytic ability, but their protective agents tend to quench the free radicals generated by the system and reduce its luminous efficiency. Therefore, a specific protective agent is further designed by screening to ensure that the free radicals generated by the system will not be quenched. In addition, the protective agent needs to have the function of Ru(bpy)3Cl2ECL co-reactant.
[0046] Beneficial effects: Compared with the prior art, the present invention has the following advantages:
[0047] 1. The present invention provides a new application of biocompatible metal selenide quantum dot materials as co-reactants in electrochemiluminescence reactions.
[0048] 2. The electrochemiluminescent co-reactant biocompatible metal selenide quantum dot material of the present invention has low cytotoxicity, low pollution, and high electrochemiluminescence intensity, and can be effectively applied to electrochemiluminescence sensors to improve the detection efficiency of electrochemical sensors.
[0049] 3. The electrochemiluminescent co-reactant biocompatible metal selenide quantum dot material of the present invention has the advantages of simple preparation process, mild preparation conditions, rapid and large-scale preparation, novel synthesis method, excellent water solubility and good biocompatibility of the obtained material. The biocompatible metal selenide quantum dots prepared by the present invention are a new type of nanomaterial with better performance than traditional tungsten oxide or molybdenum quantum dots. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 The synthesis process diagram of WSe2@BSA quantum dots;
[0051] Figure 2This is a transmission electron microscopy image of WSe2@BSA quantum dots prepared in the present invention;
[0052] Figure 3 This is a high-resolution X-ray photoelectron spectrum of W4f in WSe2@BSA quantum dots prepared in the present invention;
[0053] Figure 4 FTIR spectra of BSA and WSe2 quantum dots;
[0054] Figure 5 This is the TGA curve of WSe2@BSA quantum dots in atmospheric environment;
[0055] Figure 6 The electrochemiluminescence signal diagram is detected for the WSe2@BSA quantum dot material of the present invention as a co-reactant in the electrochemiluminescence reaction of ruthenium terpyridine (Ru(bpy)3Cl2);
[0056] Figure 7 Cell viability graphs after cells were cultured with different concentrations of tripropylamine (TPA) and WSe2@BSA quantum dots of the present invention for 0, 24, 48 and 72 hours;
[0057] Figure 8 The mechanism of WSe2@BSA quantum dots enhancing Ru(bpy)3Cl2 ECL in the present invention;
[0058] Fig. 9 is the number of grams of WSe2@BSA quantum dots that can be produced in each batch of experiments. DETAILED DESCRIPTION
[0059] The present invention is further described below in conjunction with the accompanying drawings and embodiments.
[0060] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources. Experimental methods without specific conditions specified in the examples are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0061] Tripropylamine: TPrA; terpyridine ruthenium: Ru(bpy)3Cl2; tungsten selenide quantum dots: WSe2; sodium tungstate: Na2WO4; sodium borohydride: NaBH4; bovine serum albumin: BSA; hydrochloric acid: HCl; phosphate buffer: PBS.
[0062] Example 1
[0063] Figure 1The invention discloses a method for preparing WSe2@BSA quantum dots, comprising the following steps: S1, dissolving 0.25 mg of Na2WO4·2H2O in 1 mL of H2O; S2, dissolving 40 mg of Se powder in 1 mL of NaBH4 (80 mg) aqueous solution, and reacting at room temperature to prepare a Se precursor solution; S3, mixing 0.32 mL of Na2WO4·2H2O solution with 15 mL of BSA (0.5 mg / mL); S4, dropping 128 μL of Se precursor solution into the mixed solution under stirring conditions of 1000 rpm; S5, adjusting the pH of the solution to 6 with 1 mol / L HCl, and standing the solution for reaction for 5 min; S6, removing impurities under centrifugal conditions of 10000G for 10 min, and the supernatant is the final WSe2@BSA quantum dots.
[0064] The supernatant was freeze-dried. The transmission electron microscopy image of WSe2@BSA quantum dots prepared in Example 1 and the high-resolution X-ray photoelectron spectrum of W4f were shown as follows: Figure 2 and Figure 3 shown. Figure 2 and 3 This proves that the present invention successfully synthesized WSe2@BSA quantum dots. Fourier transform infrared spectroscopy analysis further confirmed the presence of BSA in WSe2 quantum dots ( Figure 4 ). 3300cm -1 The broad characteristic peak at 1654 cmm is attributed to the stretching vibration of -H in BSA. -1 (amide bond I), 1534 cm -1 (amide bond II), 1308 cm -1 and 1242cm -1 The characteristic peak at (amide bond I) further proves the presence of BSA. In addition, thermogravimetric analysis (TGA) shows that the final WSe2 quantum dots contain about 60wt% BSA ( Figure 5 ). All these results indicate that BSA was successfully incorporated into the final product and WSe2@BSA quantum dots were successfully synthesized.
[0065] Example 2
[0066] A method for preparing a biocompatible tungsten selenide quantum dot (WSe2@BSA quantum dot) / DNA nanostructure comprises the following steps: S1, diluting the WSe2@BSA quantum dots prepared in Example 1 in an activation buffer containing EDC and Sulfo-NHS, and incubating at room temperature for 30 minutes to activate the carboxyl group; S2, adding a coupling buffer containing 2 μL 10 μM Linker-DNA and μL 10 μM DNA1 to the activated WSe2 quantum dots to prepare WSe2-DNA1; S3, adding a coupling buffer containing 8 μL 100 μM DNA2 to the activated WSe2 dots to prepare WSe2 dot-DNA; S4, mixing WSe2@BSA-DNA1 and WSe2@BSA-DNA2, and incubating at 37°C for 3 hours to prepare a WSe2 / DNA nanostructure.
[0067] Example 3
[0068] The application of the WSe2@BSA quantum dot material prepared in Example 1 in electrochemiluminescence includes the following contents:
[0069] When WSe2@BSA quantum dots were used as co-reactants in the electrochemiluminescence reaction, terpyridine ruthenium chloride hexahydrate was used as an electrochemiluminescence reagent, and a glassy carbon electrode was used as a working electrode. The electrochemiluminescence signal was detected using a three-electrode system of an electrochemical workstation.
[0070] Working electrode treatment: polish and grind a glassy carbon electrode with a diameter of 3 mm with 1.0 μm, 0.3 μm, and 0.05 μm Al2O3 powders in sequence to a smooth mirror surface, then put it into anhydrous ethanol and ultrasonically clean it in ultrapure water for 3 minutes, blow dry with N2, and set aside; the silver-silver chloride electrode is the reference electrode; the platinum wire electrode is the auxiliary electrode.
[0071] Electrochemiluminescence intensity detection with WSe2@BSA quantum dots as co-reactants and terpyridine ruthenium chloride hexahydrate as the luminescent reagent: a 50 μM terpyridine ruthenium chloride hexahydrate solution and a 0.1 mg / mL WSe2@BSA quantum dot solution (the supernatant in Example 1 was freeze-dried and redissolved in buffer) included a 0.1 M PBS buffer solution with a pH of 5.5 (i.e., 50 μM terpyridine ruthenium chloride hexahydrate and 0.1 mg / mL WSe2@BSA quantum dots in a PBS buffer solution with a pH of 5.5), the three-electrode system was placed in the solution, and PMT was set to 700 V when detecting the electrochemiluminescence signal, the test range was 0-1.3 V, and the electrochemiluminescence workstation recorded the electrochemiluminescence intensity, and the result was 0.03 V.
[0072] Example 4
[0073] The application of the WSe2@BSA quantum dot material prepared in Example 1 in electrochemiluminescence includes the following contents:
[0074] When WSe2@BSA quantum dots were used as co-reactants in the electrochemiluminescence reaction, terpyridine ruthenium chloride hexahydrate was used as an electrochemiluminescence reagent, and a glassy carbon electrode was used as a working electrode. The electrochemiluminescence signal was detected using a three-electrode system of an electrochemical workstation.
[0075] Working electrode treatment: polish and grind a glassy carbon electrode with a diameter of 3 mm with 1.0 μm, 0.3 μm, and 0.05 μm Al2O3 powders in sequence to a smooth mirror surface, then put it into anhydrous ethanol and ultrasonically clean it in ultrapure water for 3 minutes, blow dry with N2, and set aside; the silver-silver chloride electrode is the reference electrode; the platinum wire electrode is the auxiliary electrode.
[0076] Electrochemiluminescence intensity detection with tungsten selenide quantum dots as co-reactants and terpyridine ruthenium chloride hexahydrate as luminescent reagent: a 50 μM terpyridine ruthenium chloride hexahydrate solution and a 0.1 mg / mL WSe2@BSA quantum dot solution include a 0.1 M PBS buffer solution with a pH of 6.5 (i.e., 50 μM terpyridine ruthenium chloride hexahydrate and tungsten selenide quantum dots (0.1 mg / mL) in a PBS buffer solution with a pH of 6.5), a three-electrode system is placed in the solution, and PMT is set to 700 V when detecting the electrochemiluminescence signal, the test range is 0-1.3 V, and the electrochemiluminescence workstation records the electrochemiluminescence intensity, and the result is 0.3 V.
[0077] Example 5
[0078] The application of the WSe2@BSA quantum dot material prepared in Example 1 in electrochemiluminescence includes the following contents:
[0079] When WSe2@BSA quantum dots were used as co-reactants in the electrochemiluminescence reaction, terpyridine ruthenium chloride hexahydrate was used as an electrochemiluminescence reagent, and a glassy carbon electrode was used as a working electrode. The electrochemiluminescence signal was detected using a three-electrode system of an electrochemical workstation.
[0080] Working electrode treatment: polish and grind a glassy carbon electrode with a diameter of 3 mm with 1.0 μm, 0.3 μm, and 0.05 μm Al2O3 powders in sequence to a smooth mirror surface, then put it into anhydrous ethanol and ultrasonically clean it in ultrapure water for 3 minutes, blow dry with N2, and set aside; the silver-silver chloride electrode is the reference electrode; the platinum wire electrode is the auxiliary electrode.
[0081] Electrochemiluminescence intensity detection with WSe2@BSA quantum dots as co-reactants and terpyridine ruthenium chloride hexahydrate as luminescent reagent: a 50 μM terpyridine ruthenium chloride hexahydrate solution and a 0.1 mg / mL WSe2@BSA quantum dot solution include a 0.1 M PBS buffer solution with a pH of 7.4 (i.e., 50 μM terpyridine ruthenium chloride hexahydrate and WSe2@BSA quantum dots (0.1 mg / mL) in a PBS buffer solution with a pH of 7.4). The three-electrode system is placed in the solution, and PMT is set to 700 V when detecting the electrochemiluminescence signal, the test range is 0-1.3 V, and the electrochemiluminescence intensity is recorded by the electrochemiluminescence workstation, and the result is 0.5 V.
[0082] Example 6
[0083] The application of the WSe2@BSA quantum dot material prepared in Example 1 in electrochemiluminescence includes the following contents:
[0084] When WSe2@BSA quantum dots were used as co-reactants in the electrochemiluminescence reaction, terpyridine ruthenium chloride hexahydrate was used as an electrochemiluminescence reagent, and a glassy carbon electrode was used as a working electrode. The electrochemiluminescence signal was detected using a three-electrode system of an electrochemical workstation.
[0085] Working electrode treatment: polish and grind a glassy carbon electrode with a diameter of 3 mm with 1.0 μm, 0.3 μm, and 0.05 μm Al2O3 powders in sequence to a smooth mirror surface, then put it into anhydrous ethanol and ultrasonically clean it in ultrapure water for 3 minutes, blow dry with N2, and set aside; the silver-silver chloride electrode is the reference electrode; the platinum wire electrode is the auxiliary electrode.
[0086] Electrochemiluminescence intensity detection with WSe2@BSA quantum dots as co-reactants and terpyridine ruthenium chloride hexahydrate as luminescent reagent: a 50 μM terpyridine ruthenium chloride hexahydrate solution and a 0.1 mg / mL WSe2@BSA quantum dot solution included a 0.1 M PBS buffer solution at pH = 8.5 (i.e., 50 μM terpyridine ruthenium chloride hexahydrate and WSe2@BSA quantum dots (0.1 mg / mL) in a PBS buffer solution at pH = 8.5). The three-electrode system was placed in the solution, and PMT was set to 700 V when detecting the electrochemiluminescence signal, the test range was 0-1.3 V, and the electrochemiluminescence intensity was recorded by the electrochemiluminescence workstation, and the result was 0.6 V.
[0087] Example 7
[0088] The application of the WSe2@BSA quantum dot material prepared in Example 1 in electrochemiluminescence includes the following contents:
[0089] When WSe2@BSA quantum dots were used as co-reactants in the electrochemiluminescence reaction, terpyridine ruthenium chloride hexahydrate was used as an electrochemiluminescence reagent, and a glassy carbon electrode was used as a working electrode. The electrochemiluminescence signal was detected using a three-electrode system of an electrochemical workstation.
[0090] Working electrode treatment: polish and grind a glassy carbon electrode with a diameter of 3 mm with 1.0 μm, 0.3 μm, and 0.05 μm Al2O3 powders in sequence to a smooth mirror surface, then put it into anhydrous ethanol and ultrasonically clean it in ultrapure water for 3 minutes, blow dry with N2, and set aside; the silver-silver chloride electrode is the reference electrode; the platinum wire electrode is the auxiliary electrode.
[0091] The electrochemiluminescence intensity detection was performed with WSe2@BSA quantum dots as co-reactants and terpyridine ruthenium chloride hexahydrate as the luminescent reagent: a 50 μM terpyridine ruthenium chloride hexahydrate solution and a 0.1 mg / mL WSe2@BSA quantum dot solution included a 0.1 M PBS buffer solution at pH = 9.5 (i.e., 50 μM terpyridine ruthenium chloride hexahydrate and 0.1 mg / mL WSe2@BSA quantum dots in a PBS buffer solution at pH = 9.5). The three-electrode system was placed in the solution, and PMT was set to 700 V when detecting the electrochemiluminescence signal. The test range was 0-1.3 V, and the electrochemiluminescence intensity was recorded by the electrochemiluminescence workstation, and the result was 0.9 V.
[0092] Example 8
[0093] In this example, the WSe2@BSA quantum dot material prepared in Example 1 was used as a co-reactant in the electrochemiluminescence reaction of ruthenium terpyridine (Ru(bpy)3Cl2). The electrochemiluminescence signal was detected as follows: Figure 6 As shown, the specific experimental process is as follows: a 0.1 mg / mL WSe2@BSA quantum dot solution, a 50 μM Ru(bpy)3Cl2 solution, and a mixed solution containing 0.1 mg / mL WSe2@BSA quantum dots and 50 μM Ru(bpy)3Cl2 were prepared with a 0.1 M PBS (pH = 7.4) buffer solution, and then the electrochemical luminescence intensity of the above three solution systems was measured at 700 V using a glassy carbon electrode according to the method of Example 3, as shown in FIG. Figure 6 shown. Figure 6 This indicates that single WSe2@BSA quantum dots do not show ECL signals, indicating that they are not ECL emission sources. The electrochemical luminescence intensity of WSe2@BSA quantum dot materials as co-reactants is significantly enhanced several times compared to that of Ru(bpy)3Cl2 alone, indicating that the electrochemical luminescence intensity can be effectively improved by using the electrochemical luminescence co-reactant WSe2@BSA quantum dot materials of the present invention in electrochemical luminescence, and is comparable to the intensity improved by the existing co-reactant TPrA.
[0094] Example 9
[0095] Cell counting kit-8 (CCK-8) detection Figure 7 The specific experimental process is as follows: S1. Prepare cell suspension: resuspend the collected LO2 cell culture medium, count with a hemocytometer, and dilute to 5×10 4 / mL of single cell suspension. S2. Inoculation of cell suspension: Inoculate the cell suspension in a 96-well plate, 100μL per well, and design different concentration groups at the same time. Each concentration group can be designed with 5 replicate wells, and set up blank group and control group. S3. Preculture: Place the culture plate in an incubator for preculture for about 24 hours (37°C, 5% CO2). S4. Add the test substance: Add WSe2@BSA quantum dots with a final concentration of 0.1mg / mL, 1mg / mL, 5mg / mL, and 20mg / mL and TPrA with a final concentration of 1μg / mL, 10μg / mL, 0.1mg / mL, and 0.5mg / mL to each well of the culture plate, and place it in an incubator for incubation for 0, 24, 48, and 72 hours. S5. Add CCK-8 solution: Add 10 μL CCK-8 solution to each well. After adding the reagent, gently shake the culture plate to help mix. Use a microplate reader to measure the OD value at a wavelength of 450 nm, which can indirectly reflect the number of living cells. There is a significant difference in cytotoxicity between WSe2@BSA quantum dots and traditional co-reactants such as TPrA. TPrA significantly reduced cell viability (0.1 mg / mL, 45% and 31% after 24 and 72 hours, respectively), but WSe2@BSA quantum dots showed minimal cytotoxicity, and even at a higher concentration (20 mg / mL), cell viability remained above 90% after 72 hours. This excellent biocompatibility makes WSe2@BSA quantum dots a promising candidate for biomedical applications.
[0096] Example 10
[0097] Effects of different factors on the electrochemiluminescence of prepared quantum dot materials
[0098] 1. According to the method of Examples 3-7, adjust different pH values, and record the electrochemiluminescence intensity at the electrochemiluminescence workstation. Figure 8 As shown in a, there is an obvious correlation between pH value and the electrochemiluminescence intensity of the Ru(bpy)3Cl2 / WSe2@BSA quantum dot array system. As the pH value increases from 5.5 to 10.5, the pH gradually increases and the ECL intensity gradually increases, indicating that deprotonation plays a key role in the ECL process.
[0099] 2. According to the method of Example 1, BSA was replaced with an equal amount of Cys (cysteine), MEA (mercaptoethylamine) or MPA (mercaptopropionic acid), and the electrochemical luminescence intensity of WSe2 quantum dots prepared by different surfactants was measured according to the method of Example 5. Figure 8 As shown in (b), the amino-containing Cys and MEA molecular system mimics the behavior of BSA and shows stronger ECL intensity than the control. In contrast, the MPA system containing only carboxyl groups does not have this effect. This result strongly suggests that the BSA amino groups on the WSe2 surface undergo deprotonation during the ECI reaction, leading to the observed enhancement effect.
[0100] 3. According to the method of Example 1, WSe2@BSA was replaced by WS2@BSA or AuNPs-BSA, and the electrochemical luminescence intensity of different co-reactant quantum dots was measured according to the method of Example 5. Figure 8 As shown in Figure c, BSA alone has poor core reactant properties for the ECL of Ru(bby)3Cl2, which means that WSe2 plays a more important role than just providing a surface for BSA adsorption, while WS2@BSA dots and AUNPs-BSA dot do not show such core reactant effect. These results indicate that the electrocatalytic effect of WSe2 is crucial for the oxidation of BSA by amino groups during the ECL process.
[0101] 4. According to the differential pulse voltammetry (DPV) results ( Figure 8 d), Possible ECL enhancement mechanism of Ru(bpy)3Cl2 / WSe2@BSA quantum dots system Figure 8 As shown in e.
[0102] Embodiment 11
[0103] The preparation method of Example 1 of the present invention is compared with the existing preparation method of quantum dots (such as tungsten oxide or defective tungsten oxide). The results are shown in Tables 1 and Fig. 9 shown.
[0104] The method of the present invention has significant advantages over previously reported methods that usually require high temperatures and long reaction times. The reaction is carried out at room temperature and is very fast, taking only 5 minutes to complete. In addition, each batch of product freeze-dried can produce nearly 2 grams of WSe2@BSA quantum dots, enough for 1 million clinical biological tests.
[0105] Table 1 is a comparison of the preparation method of Example 1 with other reported methods
[0106]
[0107]
[0108] [1]MMRichter,Chem.Rev.2004,104,3003-3036;b)WJMiao,Chem.Rev.2008,108,2506-2553;c)LZHu,GBXu,Chem.Soc.Rev.2010 ,39,3275-3304;d)GLHong,CPSu,MCLai,ZNHuang,ZMWeng,YLChen,HHDeng,W.Chen,HPPeng,Anal.Chem.2022,94,12500-12506.
[0109] [2]XQLiu,LHSi,WXNiu,HJLi,GBXu,Angew.Chem.Int.Ed.2007,46,421-424;b)WLGuo,H.Ding,P.Zhou,YFWang,B.Su,Angew.Chem.Int.E d.2020,59,6745-6749;c)Irkham,T.Watanabe,A.Fiorani,G.Valenti,F.Paolucci,Y.Einaga,J.Am.Chem.Soc.2016,138,15636-15641.
[0110] [3]NNWang,H.Gao,YZLi,GMLi,WWChen,ZCJin,JPLei,Q.Wei,HXJu,Angew.Chem.Int.Ed.2021,60,197-201.
[0111] [4]a)YMLong,L.Bao,JYZhao,ZLZhang,DWPang,Anal.Chem.2014,86,7224-7228;b)S.Carrara,F.Arcudi,M.Prato,L.De Cola,Angew.Chem.76,741,Int.Ed.
[0112] [5]HHXing,QFZhai,XWZhang,J.Li,EKWang,Anal.Chem.2018,90,2141-2147.
[0113] [6]W.Zhan,J.Alvarez,RMCrooks,J.Am.Chem.Soc.2002,124,13265-13270;S.Voci,R.Duwald,S.Grass,DJHayne,L.Bouffier,PSFrancis,J .Lacour,N.Sojic,Chem.Sci.2020,11,4508-4515;c)TBGao,JJZhang,JWen,XXYang,HBMa,DKCao,DCJiang,Anal.Chem.2020,92,1268-1
Claims
1. A method for preparing biocompatible metal selenide quantum dots, characterized in that: The steps include: (1) dissolving a VIB Group metal salt in water to obtain a VIB Group metal salt aqueous solution; (2) dissolving selenium powder in sodium borohydride to obtain a selenium precursor solution; (3) mixing and stirring a VIB group metal salt solution with molecules containing amino groups and thiol groups, adding a selenium precursor solution, and adjusting the pH value to react; (4) Centrifuging the above system and taking the supernatant, which is the biocompatible metal selenide quantum dots.
2. The preparation method according to claim 1, characterized in that: The VIB group metal salt in step (1) is sodium tungstate, sodium molybdate or sodium chromate.
3. The preparation method according to claim 1, characterized in that: In step (3), the mass ratio of the VIB group metal salt to the selenium powder is 1:50-100.
4. The preparation method according to claim 1, characterized in that: The amino- and thiol-containing molecules in step (3) are preferably bovine serum albumin (BSA), cysteine or mercaptoethylamine.
5. The preparation method according to claim 1, characterized in that: In step (3), HCl is used to adjust the pH of the solution to 6-7, and the reaction time is 4-6 minutes.
6. Biocompatible metal selenide quantum dots prepared by the preparation method of claim 1.
7. Use of the biocompatible metal selenide quantum dots according to claim 6 as a co-reactant in an electrochemiluminescence reaction.
8. The use according to claim 7, characterized in that: When the biocompatible metal selenide quantum dots are used as a co-reactant in an electrochemiluminescence reaction, terpyridine ruthenium or its derivatives are used as electrochemiluminescence reagents; biocompatible metal selenide quantum dots are added to a solution of terpyridine ruthenium or its derivatives, and an electrochemiluminescence workstation is used to detect electrochemiluminescence signals.
9. An electrochemiluminescent system, characterized in that: The invention comprises biocompatible metal selenide quantum dots as a coreactant of an electrochemiluminescent reaction and terpyridine ruthenium as an electrochemiluminescent reagent. The biocompatible metal selenide quantum dots are the biocompatible metal selenide quantum dots prepared according to claim 1.
10. An electrochemiluminescence sensor, characterized in that: The invention comprises biocompatible metal selenide quantum dots as a co-reactant of an electrochemiluminescent reaction, terpyridine ruthenium as an electrochemiluminescent reagent, and a three-electrode system, wherein the biocompatible metal selenide quantum dots are the biocompatible metal selenide quantum dots prepared according to claim 1.
